Volume 9, Issue 2 (2023)
IEM 2023, 9(2): 167-178 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hemat jouy S, Lotfi F, Akrami R, shahraki J, Sheervalilou R, Shahraki O et al . Investigating the Association between COVID-19 Prognosis and Demographic and Clinical Features, Underlying Diseases, and Drug and Supplement Use in Patients Hospitalized in Zabol, Iran: A Single-Center Retrospective Study. IEM 2023; 9 (2) :167-178
URL: http://iem.modares.ac.ir/article-4-63392-en.html
URL: http://iem.modares.ac.ir/article-4-63392-en.html
Shaghayegh Hemat jouy1 
, Farzan Lotfi2 , Rahim Akrami3 , Jafar Shahraki2 , Roghayeh Sheervalilou4 , Omolbanin Shahraki * 
5, Habib Ghaznavi4
, Farzan Lotfi2 , Rahim Akrami3 , Jafar Shahraki2 , Roghayeh Sheervalilou4 , Omolbanin Shahraki * 5, Habib Ghaznavi4
1- Department of Exercise Physiology, Faculty of Physical Education and Sport Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran
2- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zabol University of Medical Sciences, Zabol, Iran
3- Department of Epidemiology & Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4- Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
5- Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran ,o.shahraki@zaums.ac.ir
2- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zabol University of Medical Sciences, Zabol, Iran
3- Department of Epidemiology & Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4- Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
5- Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran ,
Abstract: (816 Views)
Backgrounds: The primary goal of this study was to identify the potential association between COVID-19 prognosis and demographic and clinical features, underlying diseases, and drug and supplement use in patients admitted to Amir al-Momenin hospital in Zabol.
Materials & Methods: This retrospective study surveyed the electronic health records of 848 COVID-19 patients hospitalized in a tertiary referral hospital in southeastern Iran from the beginning of the COVID-19 outbreak until the end of February 2021. Univariate and multiple analytical tests including unconditional and penalized logistic regressions were used for statistical analysis.
Findings: Out of a total of 848 patients, 371 (43.75%) patients were female, and 477 (56.25%) patients were male. Age, underlying pulmonary and cardiovascular diseases, and loss of consciousness predicted a higher mortality rate. On the contrary, a negative chest X-ray was associated with a lower risk of death.
Conclusion: Identifying predisposing factors of mortality in COVID-19 patients will help physicians provide more intensive care to those at higher risk of death by classifying patients based on risk factors and underlying diseases.
Materials & Methods: This retrospective study surveyed the electronic health records of 848 COVID-19 patients hospitalized in a tertiary referral hospital in southeastern Iran from the beginning of the COVID-19 outbreak until the end of February 2021. Univariate and multiple analytical tests including unconditional and penalized logistic regressions were used for statistical analysis.
Findings: Out of a total of 848 patients, 371 (43.75%) patients were female, and 477 (56.25%) patients were male. Age, underlying pulmonary and cardiovascular diseases, and loss of consciousness predicted a higher mortality rate. On the contrary, a negative chest X-ray was associated with a lower risk of death.
Conclusion: Identifying predisposing factors of mortality in COVID-19 patients will help physicians provide more intensive care to those at higher risk of death by classifying patients based on risk factors and underlying diseases.
Article Type: Original Research |
Subject:
Virology
Received: 2022/08/6 | Accepted: 2023/06/14 | Published: 2023/08/19
Received: 2022/08/6 | Accepted: 2023/06/14 | Published: 2023/08/19
References
1. 1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. [DOI:10.1038/s41586-020-2008-3] [PMID] []
2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. [DOI:10.1038/s41586-020-2012-7] []
3. Gorbalenya AE, Baker SC, Baric R, Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses-a statement of the Coronavirus Study Group. BioRxiv. 2020. [DOI:10.1101/2020.02.07.937862]
4. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: Old tricks for new challenges. Crit Care. 2020;24(1):91. [DOI:10.1186/s13054-020-2818-6] []
5. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69-71. [DOI:10.5582/bst.2020.01020] [PMID]
6. Ghaznavi H, Mohammadghasemipour Z, Shirvaliloo M, Momeni MK, Metanat M, Gorgani F, et al. Short-term celecoxib (celebrex) adjuvant therapy: A clinical trial study on COVID-19 patients. Inflammopharmacology. 2022;30(5):1645-57. [DOI:10.1007/s10787-022-01029-4] []
7. Sheervalilou R, Shirvaliloo M, Dadashzadeh N, Shirvalilou S, Shahraki O, Pilehvar‐Soltanahmadi Y, et al. COVID‐19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019‐nCoV disease. J Cell Physiol. 2020;235(12):8873-924. [DOI:10.1002/jcp.29735] [PMID] []
8. Sheervalilou R, Shirvaliloo M, Sargazi S, Bahari S, Saravani R, Shahraki J, et al. Convalescent blood: Current perspective on the efficacy of a legacy approach in COVID-19 treatment. Blood Purif. 2022;51(1):1-14. [DOI:10.1159/000513164] [PMID] []
9. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653. [DOI:10.1126/scitranslmed.aal3653] [PMID] []
10. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. [DOI:10.5582/bst.2020.01047]
11. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. [DOI:10.1038/s41422-020-0282-0] [PMID] []
12. Raoult D, Hsueh PR, Stefani S, Rolain JM. COVID-19 therapeutic and prevention. Int J Antimicrob Agents. 2020; 55(4):105937. [DOI:10.1016/j.ijantimicag.2020.105937] [PMID] []
13. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. [DOI:10.1016/j.pharmthera.2020.107512] []
14. Amsden G. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. 2005;55(1):10-21. [DOI:10.1093/jac/dkh519] [PMID]
15. Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. [DOI:10.1016/j.ijantimicag.2020.105949] [PMID] []
16. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome (CRS) in severe COVID-19: Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. [DOI:10.1016/j.ijantimicag.2020.105954] [PMID] []
17. World Health Organization. Coronavirus disease 2019 (COVID-19): Situation report, 73. Geneva: World Health Organization; 2020.
18. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-42. [DOI:10.1001/jama.2020.2648] [PMID]
19. Jalili M, Payandemehr P, Saghaei A, Sari HN, Safikhani H, Kolivand P. Characteristics and mortality of hospitalized patients with COVID-19 in Iran: A national retrospective cohort study. Ann Intern Med. 2021;174(1):125-7. [DOI:10.7326/M20-2911] [PMID] []
20. Arman A, Tajik M, Nazemipour M, Ahmadinejad Z, Shahrestanaki SK, Hazrati E, et al. Risk factors of developing critical conditions in Iranian patients with COVID-19. Glob Epidemiol. 2021;3:100046. [DOI:10.1016/j.gloepi.2020.100046] []
21. Nikpouraghdam M, Farahani AJ, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in Iran: A single center study. J Clin Virol. 2020;127:104378. [DOI:10.1016/j.jcv.2020.104378] [PMID] []
22. Zali A, Gholamzadeh S, Mohammadi G, Looha MA, Akrami F, Zarean E, et al. Baseline characteristics and associated factors of mortality in COVID-19 patients; an analysis of 16000 cases in Tehran, Iran. Arch Acad Emerg Med. 2020;8(1):e70.
23. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-8. [DOI:10.1016/j.jaci.2020.04.006] [PMID] []
24. Brusselaers N, Steadson D, Bjorklund K, Breland S, Stilhoff Sörensen J, Ewing A, et al. Evaluation of science advice during the COVID-19 pandemic in Sweden. Humanit Soc Sci Commun. 2022;9(1):91.
https://doi.org/10.1057/s41599-022-01254-w [DOI:10.1057/s41599-022-01097-5] [PMID] []
25. Zheng F, Tang W, Li H, Huang Y, Xie Y, Zhou Z. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24(6):3404-10.
26. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory, and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. [DOI:10.1016/j.tmaid.2020.101623] []
27. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1-6. [DOI:10.1016/j.jinf.2020.03.004] [PMID] []
28. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372-9. [DOI:10.1164/rccm.202003-0543OC] [PMID] []
29. Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-76. [DOI:10.1056/NEJMoa030747]
30. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. Morb Mortal Wkly Rep. 2020;69(15):458-64. [DOI:10.15585/mmwr.mm6915e3] [PMID] []
31. Dadras O, SeyedAlinaghi S, Karimi A, Shamsabadi A, Qaderi K, Ramezani M, et al. COVID‐19 mortality and its predictors in the elderly: A systematic review. Health Sci Rep. 2022;5(3):e657. [DOI:10.1002/hsr2.657] []
32. Garbern SC, Pryanka R, O'Reilly GM, Bills CB, Schultz M, Indi T, et al. A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries. J Glob Health. 2022;12:05039. [DOI:10.7189/jogh.12.05039] [PMID] []
33. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of dexamethasone in hospitalized patients with COVID-19-preliminary report. MedRxiv. 2020:2020-06. [DOI:10.1101/2020.06.22.20137273]
34. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu province: A multicenter descriptive study. Clin Infect Dis. 2020;71(15):706-12. [DOI:10.1093/cid/ciaa199] [PMID] []
35. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection. Radiology. 2020;295(3):685-91. [DOI:10.1148/radiol.2020200463] []
36. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9. [DOI:10.1001/jama.2020.1585] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |